The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,284.00
Bid: 12,286.00
Ask: 12,288.00
Change: 38.00 (0.31%)
Spread: 2.00 (0.016%)
Open: 12,240.00
High: 12,306.00
Low: 12,240.00
Prev. Close: 12,246.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

The high growth companies that could re-rate in a recession

Wed, 28th Jun 2023 10:55

STOXX 600 up 0.6%, techs among big gainers

*

British SME software maker Sage hits 23-year high

*

Europe stocks head for solid gains in June

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

THE HIGH GROWTH COMPANIES THAT COULD RE-RATE IN A RECESSION (0947 GMT)

The re-rating of high quality and high growth names could be on the horizon in Europe, according to BofA quant strategist Paulina Strzelinska.

While BofA prefers value over growth during the recession phase - given an increased focus on dividend returns - the expected decline in the bond yield nevertheless means high quality names could be positively impacted.

And a lot of those high quality names are also high growth, writes Strzelinska.

BofA provides a list of such names. The list spans companies that are part of the STOXX 600 and have a market cap of at least 500 million euros, and score above 60 on BofA's quality, growth and 'recession' rankings.

The likes of Danish healthcare company Novo Nordisk , French luxury giant Hermes and UK defence company BAE Systems are at the top of the list.

They are followed by France's L'Oreal, Dutch IT company Wolters Kluwer and Italy's Ferrari.

(Lucy Raitano)

TECH TAKES CHARGE IN EUROPE AS NVIDIA RETREATS (0832 GMT)

The STOXX 600 is off to a perky start today, up around 0.6% as it heads for a 0.8% gain this month. Tech stocks, led by Dutch chipmaker ASML and Germany's SAP are among the top weighted gainers on the broader index.

2023's trillion-dollar tech darling Nvidia is down nearly 4% in the premarket after a report in the Wall Street Journal on Tuesday that the U.S. is considering new restrictions on exports of AI chips to China. Nvidia, along with rivals Micron and AMD, are caught in the crossfire between China and Joe Biden's administration right now. Might this mean an edge for their competitors on the other side of the pond?

Amsterdam's AEX is outperforming the broader market, with a gain of nearly 0.7%, as is Frankfurt's DAX, with a gain of 0.8%, thanks to SAP. London's FTSE is around the middle of the pack, with a 0.4% rise on the day, thanks to Astrazeneca, up 0.6% and Sage Group, up 4.1% at a 23-year high after JPMorgan upgraded the software maker, which supplies small and medium-sized companies.

Here's your opening snapshot:

(Amanda Cooper)

EUROPEAN FUTURES RISE (0644 GMT)

European shares were set to open higher on Wednesday taking strength from a positive close on Wall Street following surprisingly upbeat data that showed the U.S. economy is weathering rising rates better than initially thought.

EuroSTOXX50 and FTSE futures were up 0.5% and 0.3% respectively, while in Asia, shares stalled amid lingering concerns over rising interest rates.

Policy makers from Fed Chair Jerome Powell to ECB's Christine Lagarde will have their chance to speak again later in the day at a central banking forum in Portugal.

With little corporate newsflow out there, chipmakers are likely to grab the attention after a WSJ report said Washington was considering new curbs on exports of artificial intelligence chips to China. China's CSI AI index was down over 3% and so Nvidia shares fell by the same magnitude in Frankfurt.

Still on AI, the CEO of business software maker SAP said he saw huge growth potential in generative AI technology.

In M&A, chemicals group Arkema announced a proposed acquisition of a majority stake in South Korean company PI Advanced Materials for 728 million euros ($796.50 million).

BEIJING LEAVES MARKET GUESSING ON YUAN (0558 GMT)

The People's Bank of China seems to like being enigmatic, throwing the market a curve ball as it fixed the yuan weaker against the dollar than many expected. Dealers had thought the firmer fix on Tuesday meant Beijing was signalling it wanted the yuan's fall to slow, or even stop. Now, not so much.

The result has been a drop in the offshore yuan back toward Monday's trough, while the market waits for some clarity on Beijing's intentions.

Sentiment was also not helped by a Wall Street Journal report that Washington is considering new restrictions on exports of artificial intelligence chips to China, which shaved 3% off Nvidia's share price.

The rest of Asia would certainly appreciate a steadier yuan since its fall puts pressure on their currencies to depreciate, to keep their exports competitive with China. Malaysia is set to be the latest to intervene to support its currency, and Japan sounds closer to pulling the trigger every day.

"We are closely watching currency moves with a strong sense of urgency," Japan's top currency diplomat warned, which is about as close as the Ministry of Finance gets to an outright ultimatum.

The last time the MOF intervened, in 2022, they sold a thumping $43 billion of dollars in just two days, so the threat is not to be sniffed at. It was enough to stall the dollar at 144.0 yen, while the euro eased off a 15-year high on the yen.

Still, the market is clearly betting the yen will keep falling unless, and until, the Bank of Japan backs away from its yield curve policy. Bank of Japan chief Ueda speaks later today at the European Central Bank's Sintra jamboree, and will have to justify his super-easy policy while every other central bank on the panel is busy tightening.

It will also be interesting to see if ECB chief Lagarde expands on the idea that firms should stop padding their margins by raising prices - a variation of the argument that this is a profit-price spiral rather than a wage-price spiral.

Once this would have been scorned as a radical view of the far-left fringe, but it's increasingly gaining mainstream acceptance. An OECD study earlier this month argued that profits were a major driver of inflation, especially in the energy and agriculture sectors.

It's tempting to think that, if wages are not the culprit, then central banks might not have to push unemployment up as much as in the past to curb inflation. Yet, Lagarde's conclusion was that policy would need to be tighter for longer so as to hurt demand enough that firms restrained their hunger for profits. That's still a recipe for higher unemployment.

On the bright side, Australian data out Wednesday did show CPI inflation slowing by more than expected to a 13-month low, and that followed a sharp slowdown in Canadian inflation. So maybe there's hope yet.

Key developments that could influence markets on Wednesday:

- ECB President Christine Lagarde, Fed's Jerome Powell, BOJ Governor Kazuo Ueda and Bank of England Governor Andrew Bailey take part in ECB panel in Sintra, Portugal, 1230 GMT

- U.S. data on wholesale and retail inventories, advance goods trade balance

(Wayne Cole)

More News
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more
26 Feb 2024 08:51

AstraZeneca's Voydeya treatment recommended for EU approval

(Alliance News) - AstraZeneca on Monday announced further support from regulators for its first-in-class blood disease treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.